Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Key Eligibility Criteria (additional criteria may apply) Part 1 Key Inclusion Criteria

1. Pathologically confirmed solid tumors, e.g., Colorectal Cancer (CRC), Non-Small Cell
Lung Cancer (NSCLC), or Pancreatic Cancer (PANC), that is metastatic, unresectable locally
advanced, or in the Investigator's opinion the subject is high risk for incurable relapse
within two years.

Part 1: Key Exclusion Criteria

   1. History of any of other malignancy in the past 5 years other than non-melanoma skin
   carcinoma, low grade localized prostate cancer, superficial bladder cancer, ductal
   carcinoma in situ (CIS) of the breast, CIS of the Cervix, or Stage I uterine cancer.

   2. Prior allogeneic stem cell transplant.

   3. Prior solid organ transplant.

Part 2 : Key Inclusion Criteria

   1. Pathologically confirmed solid tumors, e.g., Colorectal Cancer (CRC), Non-Small Cell
   Lung Cancer (NSCLC), Pancreatic Cancer (PANC), Mesothelioma, or Ovarian Cancer (OVAC)
   that is metastatic, unresectable locally advanced, or in the Investigator's opinion
   the subject is high risk for incurable relapse within two years.

   2. Participants are germline HLA-A*02 heterozygous confirmed by HLA typing.

   3. Primary tumor tissue showing LOH of HLA-A*02 by NGS testing.

   4. Eastern Cooperative Oncology Group (ECOG) 0 or 1 performance status.

Part 2: Key Exclusion Criteria

   1. History of any of other malignancy in the past 5 years other than non-melanoma skin
   carcinoma, low grade localized prostate cancer, superficial bladder cancer, ductal
   carcinoma in situ (CIS) of the breast, CIS of the Cervix, or Stage I uterine cancer.

   2. Prior allogeneic stem cell transplant.

   3. Prior solid organ transplant.

   4. Participants who have received any cancer therapy on any investigational therapy for
   any indication, including but not limited to chemotherapy, small molecules, monoclonal
   antibodies, or radiotherapy (with bone marrow impact) within 2 weeks of planned
   apheresis or 3 half-lives, whichever is shorter.

   5. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection
   (excluding fungal infections of nail beds) at study enrollment necessitating specific
   treatment, or any major episode of infection requiring treatment with Intravenous (IV)
   antimicrobials (e.g., IV antibiotics) or hospitalization (relating to completion of
   antibiotic course).

   6. Has known active central nervous system metastases. Subjects with previously treated
   brain metastases may participate upon medical monitor agreement.

   7. In the Investigator's judgement, any other condition or reason the subject would not
   complete the required study visits and procedures, and follow up visits, or comply
   with the study requirements for participation.